Intravitreal injections of an anti-VEGF monoclonal antibody (mAb), are used in wet-AMD and diabetic retinopathy (DR) to counter the overexpression of VEGF that promotes neovascularization [7]. This evidence concerns the gene VEGFA and age-related macular degeneration.